Will Eric Lefkofsky Improve Cancer Diagnosis And Treatment Through Tempus?

It is certain that Cancer is still a dilemma and continues to affect millions of people worldwide. However, the last decade has seen remarkable progress in the fight against cancer. Researchers have discovered new cancer treatments and therapies. Governments have also joined the fight and are coming up with new policies and regulations that are aimed at stemming the tide of this devastating disease worldwide. There are innovative programs, initiatives, and strategies that have been formed to help accelerate current and future developments against cancer. New companies are also coming up and are changing the way we treat cancer. One such company is Tempus, a revolutionary technology company that has built an innovative operating system that will bring a smart approach in the fight against cancer.

About Tempus

Tempus was founded in 2015 by renowned tech figures, Eric Lefkofsky and Brad Keywell. The company focuses on collecting, analyzing, and storing of large clinical data, which, according to the company’s website, will help doctors make real time, individualized, and data-driven decisions. The duo says that the start-up uses sophisticated genomic sequencing and data analysis techniques that will help come up with the next breakthrough developments in the battle against cancer.

The company works with patients who have lung, pancreatic, and breast cancer and hopes to focus on other forms of cancer over time. The innovative start-up also expects to collaborate with researchers, cancer programs, and hospitals to collect more accurate data and make their system more efficient. They recently announced that they would work with hospitals such as Northwestern’s Lurie Cancer Center, Cleveland Clinic, University of Michigan, Duke University School of Medicine, and other community cancer clinics across the country.

Eric Lefkofsky

Eric Lefkofsky is an influential American entrepreneur. He is Co-founder and the current CEO of Tempus. He is also the man behind Lightbank, a Chicago-based venture capital firm that bets on emerging and disruptive start-ups. Lefkofsky contribution in the fight against cancer did not start at Tempus; he and his wife, Elizabeth, have been making large donations to help cancer researchers come up with technologies and treatments options that can help eradicate cancer.

Thanks to his leadership skills and years of experience, the exceptional leader has been able to transform Tempus from a weak start-up into an invincible force in the medical world. The company is currently valued $700 million.

To Learn More Click Here

How Oncotarget Is Preparing For The Future

Oncotarget was launched in May 2010. Within two years it received 6.67 as its impact factor in 2012. This meant that it was a leading journal in the field of oncology as well as cancer research. Submissions to this journal are increasing in an exponential manner.This is a bi-weekly journal. There are dozens of research papers available in each issue. Such a trend indicates that Oncotarget has a bright future as it seems to attract practically all the submissions in the cancer field. This journal has received fast success. Oncotarget and its enhanced popularity have led to the launch of Oncoscience. This is a sister journal of Oncotarget. It has articles on a wide range of topics.

Oncotarget has a large Editorial Board. It has numerous sections that are headed by several associates editors. It is quite clear that the journal has highly ambitious goals.Oncotarget had been envisioned as a small journal. It was required to introduce a new concept called oncotarget. Besides, it was designed to promote a multidisciplinary approach by having a unique focus. The editors of Oncotarget wanted to keep it this way without any kind of changes. In this way, Oncotarget was supposed to be an experiment.Soon, this journal became highly successful and very popular. This is due to the passion as well as simplicity associated with it. Besides, it has an individual approach to everything.

It tries to avoid all kinds of unqualified reviewers. The evaluation of all submissions is done in parallel. It is never done in sequence. All the possibilities provided by modern technology are made use of over here.The fact remains that despite the unprecedented technical progress taking place in science and technology, the routine of nearly all the journals has remained unchanged. This is why a new paradigm was required in a scientific publication by the scientific community. This is why scientists were looking for an alternative to this kind of traditional publication.Oncotarget is a journal that allows a thorough peer-review. This is followed by rapid publication. It even allows for certain key decisions to be taken even on the day of submission. It allows for publishing on the next day post acceptance.

Eric Lefkofsky’s Achievements

Eric Lefkofsky is the CEO and co-founder of Tempus, which is a technology company that has built a super operating system to be used in battling cancer. Eric is also a founding partner of Lightbank, a company that ventures in fund investment in matters to do with disruptive technologies. On the other hand, he is the chairman and co-founder of Groupon, an e-commerce marketplace globally as well as a co-founder of Uptake Technologies. Uptake Technologies is one of the world’s largest industries in predicting analytics platform. Echo Global Logistics is a logistic outsourcing and technology-enabled transportation firm, and Inner Workings is a provider of managed promotional and print solutions globally.

Tempus mission is to redefine the way genomic data is used and applied in a clinical setting. The company’s major goal is to ensure that each and every patient benefits fully from the treatment of those individuals who come before by ensuring they provide physicians with the adequate tools that learn and gather more data. Also, the company provides transcriptomic and genomic services and analyzes germline and somatic molecular data along with therapeutical data to ensure they empower physicians to make a compelling data-driven decision.

In the year 2006, Lefkofsky together with his wife formed a charitable trust by the name Lefkofsky Family Foundation. Its mission is to support charitable and educational organizations, scientific and causes around the entire world. The Foundation’s primary purpose is to ensure that advance initiatives and high impact programs can improve the living standards of human life in the communities. The foundation focuses on human rights, education, arts and culture, and medical research. The grant making is always evaluated quarterly, and higher part of the money is focused on Chicago which is Lefkofskys’ hometown, whereby arts and culture take the largest donations.

Eric’s education support initiative focuses on Greater Chicago area where they engage in helping younger children as well as giving charters to schools, scholarship programs and after-school programs for the disadvantaged youth. The foundation also engages in supporting medical centers particularly those that care for children as well as give donations to pancreatic cancer. Also, Lefkofskys has supported research in the treatment as well as the cure for lung cancer, thyroid cancer, and leukemia. The foundation has also partnered with Motorola Mobility and Google to create 1871 FEMtech, with the hope and goal of enabling and encouraging more female tech to break into the field as entrepreneurs.